Director Tobin Schilke of Lexeo Therapeutics, Inc. filed a Form 4 on November 17, 2026, disclosing the acquisition of a stock option covering 70,000 shares of common stock, granted on November 14, 2026.
Key Highlights
- Option grant date: November 14, 2026, covering 70,000 shares of Lexeo Therapeutics common stock.
- Exercise price: $2.87 per share, as reported in the filing.
- Expiration date: November 13, 2036, according to the filing.
- Vesting schedule: 1/3 of the shares vest on each yearly anniversary of the grant date, with full vesting on November 14, 2029, subject to continuous service.
- Price paid: $0 for the derivative security at grant, as reported.
- Post-transaction holdings: 70,000 derivative securities beneficially owned directly following the reported transaction.
Lexeo Therapeutics Director Discloses Stock Option Award in November 2026 Filing
According to the Form 4 filed with the SEC on November 17, 2026, Tobin Schilke, identified as a director of Lexeo Therapeutics, Inc. (NASDAQ:LXEO), acquired a stock option to purchase 70,000 shares of the company's common stock. The transaction date is listed as November 14, 2026, and the transaction code is recorded as "A," indicating an acquisition. The filing reports that the price of the derivative security at grant was $0.
The filing discloses an exercise price of $2.87 per share and an expiration date of November 13, 2036. Per the explanation of responses in the filing, "1/3rd of the shares underlying the option shall vest, and become exercisable, on each yearly anniversary of the Grant Date, such that all shares are vested and exercisable on November 14, 2029, subject to the Reporting Person's continuous service on each such vesting date." The option is held directly and covers common stock as the underlying security.
Following the reported transaction, the filing states that Schilke beneficially owns 70,000 derivative securities directly. No non-derivative securities transactions were reported in Table I of the filing. The Form 4 was signed by Youjin Choi as Attorney-in-Fact on November 17, 2026.
What Was Disclosed
Lexeo Therapeutics director Tobin Schilke disclosed the receipt of a stock option to purchase 70,000 shares of common stock at $2.87 per share, granted November 14, 2026, with a three-year ratable vesting schedule and a 10-year term expiring November 13, 2036.




Please wait processing your request...